远红外理疗桑拿房

Search documents
融捷健康拟斥资不超1亿元开展金融衍生品交易业务
Xin Lang Cai Jing· 2025-08-26 14:21
Core Viewpoint - Rongjie Health Technology Co., Ltd. plans to engage in financial derivatives trading to mitigate foreign exchange risk associated with its export business, primarily settled in USD [1][2]. Summary by Sections Trading Overview - The company aims to conduct financial derivatives trading to hedge against foreign exchange fluctuations and reduce financial costs, focusing on non-speculative operations [1]. - The trading will involve currencies aligned with the company's primary settlement currency, including forward foreign exchange, foreign exchange swaps, currency swaps, foreign exchange options, and other financial derivatives [1]. - The trading limit is set at a maximum of RMB 100 million (or equivalent foreign currency), valid for 12 months from board approval, and can be reused [1]. Approval Process - The proposal for financial derivatives trading was approved by the company's board of directors on August 25, 2025, and does not require shareholder meeting approval [2]. Risk Analysis - The company acknowledges potential risks, including foreign exchange volatility, internal control weaknesses, liquidity issues, and legal risks associated with changes in laws or counterparty defaults [2]. - To mitigate these risks, the company has established a management system for financial derivatives trading, ensuring careful contract review and adherence to risk management protocols [2]. Impact on the Company - Engaging in financial derivatives trading is expected to help the company avoid foreign exchange market risks, lower financial costs, and enhance foreign exchange gains without adversely affecting its financial and operational status [3]. - The company will account for these transactions according to relevant accounting standards, with specific outcomes subject to audit [3].
融捷健康:2025年上半年归属股东净利润4752万元,同比增长65.72%丨财面儿
Cai Jing Wang· 2025-08-26 14:21
Core Insights - Rongjie Health reported a revenue of 433 million yuan for the first half of 2025, representing a year-on-year growth of 29.81% [1] - The net profit attributable to shareholders reached 47.52 million yuan, marking a significant increase of 65.72% compared to the previous year [1] Revenue Breakdown - The main business of the company focuses on health products, including far-infrared therapy sauna rooms, portable sauna rooms, air purifiers, and fitness equipment [1] - Revenue from far-infrared therapy sauna rooms was 309 million yuan, with a gross margin of 46.80% and a year-on-year increase of 33% [2] - Revenue from portable sauna products was 19.64 million yuan, with a gross margin of 30.21%, showing no significant year-on-year change [2] - Revenue from air purifiers was 16.53 million yuan, with a gross margin of 5.03%, reflecting a year-on-year decline of 3% [2] Investments - The company has invested in health service companies, including Yinglian Yunxiang (remote diagnosis and electronic film projects) and Lexin Management (health check-up projects) [1]